大规模符合GMP的CRISPR-Cas9介导的多病毒特异性T细胞糖皮质激素受体缺失
研究开发了符合GMP的CRISPR-Cas9技术敲除NR3C1基因(编码糖皮质激素受体)的多病毒特异性T细胞(VSTs),使其在体外和体内高剂量地塞米松存在下仍能杀伤靶细胞并增殖,并建立了快速制备高靶向活性、低脱靶编辑的GMP级NR3C1敲除VSTs的流程。
要点
- 敲除NR3C1使多病毒特异性T细胞抵抗糖皮质激素的淋巴细胞毒性作用。
- NR3C1敲除VSTs在体外和体内高剂量地塞米松存在下仍能杀伤靶细胞并成功增殖。
- 建立了快速制备高靶向活性、低脱靶编辑的GMP级NR3C1敲除VSTs的方案。
核心结论
- 基因工程改造的VSTs有望成为治疗HSCT后接受糖皮质激素治疗的患者危及生命的病毒感染的新方法。
研究设计与样本
- 开发了利用CRISPR-Cas9基因编辑技术快速制备符合GMP级的糖皮质激素抵抗的多病毒特异性T细胞(VSTs)的新策略。
主要发现
- 敲除NR3C1(编码糖皮质激素受体的基因)使VSTs对糖皮质激素的淋巴细胞毒性作用产生抵抗。
- NR3C1敲除VSTs在体外和体内高剂量地塞米松存在下均能杀伤靶细胞并成功增殖。
- 建立了快速制备高靶向活性、低脱靶编辑的GMP级NR3C1敲除VSTs的方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Virus-specific T cells have proven highly effective for the treatment of severe and drug-refractory infections after hematopoietic stem cell transplant (HSCT). However, the efficacy of these cells is hindered by the use of glucocorticoids, often given to patients for the management of complications such as graft-versus-host disease. To address this limitation, we have developed a novel strategy for the rapid generation of good manufacturing practice (GMP)-grade glucocorticoid-resistant multivirus-specific T cells (VSTs) using clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) gene-editing technology. We have shown that deleting the nuclear receptor subfamily 3 group C member 1 (NR3C1; the gene encoding for the glucocorticoid receptor) renders VSTs resistant to the lymphocytotoxic effect of glucocorticoids. NR3C1-knockout (KO) VSTs kill their targets and proliferate successfully in the presence of high doses of dexamethasone both in vitro and in vivo. Moreover, we developed a protocol for the rapid generation of GMP-grade NR3C1 KO VSTs with high on-target activity and minimal off-target editing. These genetically engineered VSTs promise to be a novel approach for the treatment of patients with life-threatening viral infections post-HSCT on glucocorticoid therapy.
引用
- Basar R, Daher M, Uprety N, et al. Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood Adv. 2020. PMID: 32717029. doi:10.1182/bloodadvances.2020001977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。